Literature DB >> 8532183

(+/-)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex.

J Gleitz1, A Beile, T Peters.   

Abstract

Kava pyrones are pharmacologically active compounds extracted from Piper methysticum Forst. Because kava pyrones were characterized by their anticonvulsive, analgesic and centrally muscle relaxing action, we investigated the influence of (+/-)-kavain, a synthetic kava pyrone, on veratridine-stimulated increase in intrasynaptosomal Na+ concentration ([Na+]i) of rat cerebrocortical synaptosomes. [Na+]i was measured spectrofluorometrically employing SBFI as Na+ sensitive fluorescence dye. Veratridine (5 mumol/I) enhanced basal [Na+]i 6.6-fold from 11.3 to 74.1 mmol/l Na+. Incubation of synaptosomes for 100 sec with (+/-)-kavain was sufficient to reduce dose dependently the stimulated increase of [Na+]i with an IC50 value of 86.0 mumol/l, and almost complete inhibition of Na(+)-channels was attained with 400 mumol/l) reduced veratridine-elevated [Na+]i to 30.4% and 7.9% of control whereas the centrally acting muscle relaxant mephenesin (400 mumol/l) was without any effect. Postapplication of 400 mumol/l (+/-)-kavain or 10 mumol/l TTX immediately diminished veratridine-elevated [Na+]i to nearly basal levels with a half life time of 69.7 and 41.8 sec, respectively. To study the influence of (+/-)-kavain on non stimulated synaptosomes, an increase in [Na+]i was induced by 200 mumol/l ouabain, which enhanced [Na+]i hyperbolically with an initial rate of 18.4 mmol Na+/l min. Preincubation of synaptosomes with 400 mumol/l (+/-)-kavain or 10 mumol/l TTX partly prevented Na(+)-influx for both compounds to the same extent of about 57% of control. The presented data indicate a fast and specific inhibition of voltage-dependent Na(+)-channels by (+/-)-kavain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8532183     DOI: 10.1016/0028-3908(95)00090-s

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

Review 1.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 2.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Characterization of the participation of sodium channels on the rise in Na+ induced by 4-aminopyridine (4-AP) in synaptosomes.

Authors:  Emilio Galván; María Sitges
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

4.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.